Vertex Pharmaceuticals (NQ:VRTX)

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore

January 10, 2025

From Zai Lab Limited

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗

January 07, 2025

Via Benzinga

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Topics Artificial Intelligence Government

Vertex Grapples With Bearish Chart As Death Cross Emerges ↗

January 07, 2025

Via Benzinga

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip ↗

December 28, 2024

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 26, 2024

Via Benzinga

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip ↗

December 26, 2024

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK...

Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals ↗

December 24, 2024

Via Talk Markets

Topics Stocks / Equities

3 No-Brainer Stocks to Buy on the Latest Sell-Off ↗

December 24, 2024

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

December 23, 2024

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst ↗

December 23, 2024

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients.

Via Benzinga

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 23, 2024

Via Benzinga

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings.

Via Benzinga

Topics Economy

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? ↗

December 22, 2024

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗

December 21, 2024

My Top 10 Stocks to Buy for 2025 ↗

December 21, 2024

The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock.

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock ↗

December 20, 2024

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 20, 2024

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

December 20, 2024

Micron, Vertex, Novo Nordisk and Nike were notable losers on news.

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Topics Economy

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? ↗

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 19, 2024

Via Benzinga

December 19, 2024

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.

Via Benzinga

Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain ↗

December 19, 2024

The company says there was variability among placebo responses at various sites.

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. ↗

December 19, 2024

Vertex Pharmaceuticals' drug reduced back pain significantly.

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

December 19, 2024

2 Unstoppable Stocks to Buy and Hold for the Next Decade ↗

December 19, 2024

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗

December 17, 2024